Sveriges mest populära poddar

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

3 min•13 maj 2026

In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, Eli Lilly releases data from two late-phase trials showing patients maintained meaningful weight loss after transitioning from higher-dose injectable GLP-1 therapies, and Hope Mueller argues that true pharmaceutical expertise is defined not just by having answers but by recognizing when you need a reset.

Fler avsnitt av Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves Datroway

22 maj•2 min

Pharmaceutical Executive Daily: What It Takes to Move Machine Learning

21 maj•3 min

Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio

20 maj•4 min

Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs

19 maj•3 min

Rethinking Pharma's Go-to-Market Formula

19 maj•21 min

Pharmaceutical Executive Daily: FDA Approves Baxdrostat

18 maj•2 min

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

15 maj•3 min

Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi

14 maj•4 min

Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen

11 maj•3 min

Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA

8 maj•2 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.